/
LMAT
$96.00+$0.34 (+0.36%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.2B
23M shares
52-week range
$79.01 – $118.01
44% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$35.43
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $105.6M | $117.2M | $129.4M | $154.4M | $161.7M | $193.5M | $219.9M | $249.6M |
| Cost of revenue | $31.6M | $37.4M | $44.7M | $53.0M | $56.8M | $66.4M | $69.0M | $71.1M |
| Gross profit | $73.9M | $79.9M | $84.6M | $101.4M | $104.9M | $127.0M | $150.9M | $178.5M |
| Gross margin | 70.0% | 68.1% | 65.4% | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
| R&D | $8.2M | $9.3M | $10.1M | $11.8M | $13.3M | $17.0M | $15.7M | $14.1M |
| Operating income | $28.2M | $21.2M | $28.8M | $36.4M | $26.8M | $36.7M | $52.3M | $67.9M |
| EBITDA | $32.8M | $27.1M | $36.9M | $46.0M | $36.9M | $49.0M | $66.8M | $90.8M |
| Net income | $22.9M | $17.9M | $21.2M | $26.9M | $20.6M | $30.1M | $44.0M | $57.7M |
| Net margin | 21.7% | 15.3% | 16.4% | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
| EPS (diluted) | 1.13 | 0.88 | 1.04 | 1.25 | 0.93 | 1.34 | 1.93 | 2.52 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $280M | $3.00 | $2.97–$3.02 | 6 |
| 2027 | $306M | $3.26 | $3.23–$3.29 | 6 |
| 2028 | $333M | $3.51 | $3.40–$3.65 | 4 |
| 2029 | $350M | $0.00 | $0.00–$0.00 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$109.80
Price
$96.00
Implied upside
+14%
Peer comparison
LeMaitre Vascular, Inc.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
www.lemaitre.com- Employees
- 655
- IPO / List date
- Oct 19, 2006
- HQ
- BURLINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds LMAT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 138,502 | $15.1M |
| Bridgewater Associatesas of 2024-12-31 | 2,353 | $216.8K |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 0.94% ($0.90/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-21 | $0.2500 | 2026-06-04 |
| 2026-03-12 | $0.2500 | 2026-03-26 |
| 2025-11-20 | $0.2000 | 2025-12-04 |
| 2025-08-21 | $0.2000 | 2025-09-04 |
| 2025-05-15 | $0.2000 | 2025-05-29 |
| 2025-03-13 | $0.2000 | 2025-03-27 |
| 2024-11-21 | $0.1600 | 2024-12-05 |
| 2024-08-15 | $0.1600 | 2024-08-29 |
| 2024-05-15 | $0.1600 | 2024-05-30 |
| 2024-03-13 | $0.1600 | 2024-03-28 |
Recent trades on TradeandTell
No one on the platform has traded LMAT yet.
